9Bio Therapeutics joins adMare BioInnovations’ National Therapeutics Accelerator
Quebec City, May 21, 2024 – 9Bio Therapeutics, a biotech company pioneering next-generation oncology therapeutics, is proud to announce its acceptance into the adMare BioInnovations National Therapeutics (Tx) Accelerator. This strategic partnership aims to advance 9Bio’s mission of developing targeted cancer therapies that prioritize patient safety and treatment efficacy.
9Bio’s innovative approach leverages a proprietary AI-assisted structural biology platform that integrates anatomical and biochemical contexts. This technology is designed to engineer drugs that selectively target tumor cells, minimizing impact on healthy tissues. Currently, 9Bio’s pipeline includes three therapies in the discovery phase, each poised to offer new hope in cancer treatment.
“Joining the adMare National Tx Accelerator is an important milestone for 9Bio,” said Henrique De Carvalho, CEO and Co-founder of 9Bio Therapeutics. “This collaboration provides us with invaluable resources and expertise to accelerate the development of our therapies, bringing us closer to offering innovative solutions for cancer patients.”
The adMare National Tx Accelerator partners with early-stage Canadian therapeutic ventures, offering comprehensive support including scientific and business development guidance, intellectual property and legal assistance, financial support, and access to a vast professional network. This tailored program is designed to help companies like 9Bio achieve critical milestones in therapeutic development and commercialization within Canada.
“We’re thrilled to welcome 9Bio to our Accelerator,” said Clara Ducord, Manager at the National Tx Accelerator. “We want to help these companies innovate and grow; that’s how the program works with partners in the sector, hopefully leading to advancements in life sciences and creating high-value economic opportunities nationwide.”
Click here to read the official announcement from adMare BioInnovations.
About 9Bio Therapeutics
9Bio Therapeutics is a biotech company committed to developing innovative oncology therapeutics. Our AI-guided structural biology platform integrates anatomical and biochemical contexts to design drugs that selectively target tumors. Using this approach, we generate medicines with specificity for tumors that spare healthy tissues, improving safety, efficacy, and opening the door to previously underexploited therapeutic modalities. Our pipeline includes three discovery-stage therapies: an antibody-drug conjugate (ADC) targeting tumor cells, an ADC targeting tumor-subverted immune cells, and an engineered cytokine.
About adMare BioInnovations
With a strong track record of globally-competitive scientific discovery, Canadian life sciences are primed to lead the world. To make this a reality, adMare BioInnovations uses its scientific and commercial expertise, specialized R&D infrastructure, and seed capital to build strong life sciences companies, develop robust ecosystems, and foster industry-ready talent. It re-invests its returns into the Canadian industry to ensure its long-term sustainability. adMare currently has 29 portfolio companies that have attracted $2.3 billion of risk capital, have a combined value of $4 billion, and have created over 1,000 jobs in Canada. For more information, please go to www.admarebio.com.